Kaur et al. demonstrated that overexpression of the PP2A inhibitor protein PME-1 drives glioma cell resistance to various multikinase inhibitors through specific PP2A complexes and a decrease in histone deacetylase 4 cytoplasmic activity. Here, PPME1 is linked to central nervous system cancer.